266 related articles for article (PubMed ID: 27060889)
1. A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.
Tighiouart M; Li Q; Rogatko A
Stat Med; 2017 Jan; 36(2):280-290. PubMed ID: 27060889
[TBL] [Abstract][Full Text] [Related]
2. Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.
Tighiouart M; Piantadosi S; Rogatko A
Stat Med; 2014 Sep; 33(22):3815-29. PubMed ID: 24825779
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
Tighiouart M; Cook-Wiens G; Rogatko A
J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
[TBL] [Abstract][Full Text] [Related]
4. Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.
Wheeler GM; Sweeting MJ; Mander AP
Stat Med; 2017 Jul; 36(16):2499-2513. PubMed ID: 28295513
[TBL] [Abstract][Full Text] [Related]
5. Modelling semi-attributable toxicity in dual-agent phase I trials with non-concurrent drug administration.
Wheeler GM; Sweeting MJ; Mander AP; Lee SM; Cheung YK
Stat Med; 2017 Jan; 36(2):225-241. PubMed ID: 26891942
[TBL] [Abstract][Full Text] [Related]
6. Identifying a maximum tolerated contour in two-dimensional dose finding.
Wages NA
Stat Med; 2017 Jan; 36(2):242-253. PubMed ID: 26910586
[TBL] [Abstract][Full Text] [Related]
7. Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information.
Zhang Y; Kutner M; Chen Z
Biom J; 2021 Oct; 63(7):1476-1492. PubMed ID: 33969525
[TBL] [Abstract][Full Text] [Related]
8. Designs for phase I trials in ordered groups.
Conaway MR; Wages NA
Stat Med; 2017 Jan; 36(2):254-265. PubMed ID: 27624880
[TBL] [Abstract][Full Text] [Related]
9. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
10. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
Chen Z; Tighiouart M; Kowalski J
Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
[TBL] [Abstract][Full Text] [Related]
11. Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents.
Jimenez JL; Tighiouart M; Gasparini M
Biom J; 2019 Mar; 61(2):319-332. PubMed ID: 29808507
[TBL] [Abstract][Full Text] [Related]
12. Escalation with overdose control for phase I drug-combination trials.
Shi Y; Yin G
Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
[TBL] [Abstract][Full Text] [Related]
13. Randomized dose-escalation designs for drug combination cancer trials with immunotherapy.
Mozgunov P; Jaki T; Paoletti X
J Biopharm Stat; 2019; 29(2):359-377. PubMed ID: 30352007
[TBL] [Abstract][Full Text] [Related]
14. A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials.
Tighiouart M; Li Q; Piantadosi S; Rogatko A
Am J Biostat; 2016; 6(1):1-11. PubMed ID: 28706582
[TBL] [Abstract][Full Text] [Related]
15. Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.
Diniz MA; Quanlin-Li ; Tighiouart M
J Biom Biostat; 2017; 8(6):. PubMed ID: 29552377
[TBL] [Abstract][Full Text] [Related]
16. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
17. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
Paoletti X; Kramar A
Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
[TBL] [Abstract][Full Text] [Related]
18. A Bayesian Adaptive Design in Cancer Phase I Trials using Dose Combinations in the Presence of a Baseline Covariate.
Diniz MA; Kim S; Tighiouart M
J Probab Stat; 2018; 2018():. PubMed ID: 30906326
[TBL] [Abstract][Full Text] [Related]
19. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
Tighiouart M; Rogatko A; Babb JS
Stat Med; 2005 Jul; 24(14):2183-96. PubMed ID: 15909291
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase I Bayesian dose escalation design for the combination of anti-cancer drugs.
Dejardin D; Lesaffre E; Hamberg P; Verweij J
Pharm Stat; 2014; 13(3):196-207. PubMed ID: 24715683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
